c4therapeutics.com (CCCC): חוב להון עצמי

The price history of C4 Therapeutics, Inc. (CCCC) demonstrates a standalone debt-to-equity ratio of 0.24. C4 Therapeutics, Inc. (CCCC) generates revenue by licensing an innovative platform designed to combat severe oncological diseases. Its technology stack leverages AI and robotics to rapidly identify protein degradation formulas. Meanwhile, the business faces a liquidity shortage and is depleting reserves on costly research.

The analyst assesses the credit quality of C4 Therapeutics, Inc. (CCCC) through its liability structure. Planned laboratory utilization and partners' readiness for drug launches confirm the business's operational stability. This change in the debt-to-equity ratio measures the proportion of external debt relative to owner assets. A low ratio minimizes risks during rate hikes, creating a financial buffer. Investors should use this indicator to monitor leverage sustainability.